

VII. BIBLIOGRAFÍA

1. Cotran R, Kumar V, Robbins SL editores. Patología estructural y funcional, 4ª edición. Madrid: Interamericana-McGraw-Hill; 1990.
2. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America. *Clin Infect Dis* 1998; 26: 811-38.
3. Niederman MS, Mandel LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assesment of severity, antimicrobial therapy, and prevention. American Thoracic Society. *Am J Respir Crit Care Med* 2001;163: 1730-54.
4. Dorca J, Bello S, Blanquer J, Celis R, Molinos L, Torres A, et al. Diagnóstico y tratamiento de la neumonía de adquisición comunitaria. *Arch Bronconeumol* 1997;33:240-6.
5. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with pneumonia. A meta-analysis. *JAMA* 1996; 275: 134-41.
6. Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E. et al. Sever community-acquired pneumonia. Epidemiology and prognostic factors. *Am Rev Respir Dis* 1991;144: 312-8.
7. Ewig S, Torres A. Severe communituy-acquired pneumonia. *Current Opinion in Critical Care*. 2002; 8: 453-60.
8. Niederman MS, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. *Am Rev Respir Dis* 1993; 148: 1418-26.
9. British Thoracic Society. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults admitted to hospital. *Br J Hosp Med* 1993; 49;346-50.
10. Huchon G, Woodhead M, Gialdroni-Grassi G, Léophonte P, Manresa F, Schaberg T, et al. Guidelines for management of adult community-acquired lower respiratory tract infections. *Eur Respir J* 1998; 11:986-91.

11. Bartlett JG, Dowell SF, Mandel LA, File TM, Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clin Infect Dis* 2000; 31: 347-82.
12. British Thoracic Society. British Thoracic Society guideline for the management of community acquired pneumonia in adults. *Thorax* 2001, 56 (suppl 4) 1-65.
13. Ansola P, Sobradillo V, Baranda F, Gaztelurrutia L, Llorente JL, Antoñana JM. Neumonías adquiridas en la comunidad de Vizcaya. *Arch Bronconeumol* 1990; 26: 103-7.
14. Roig Cutillas J, Martínez Benazet J, Domingo Ribas C. Concepto y diagnóstico diferencial de la neumonía. *Arch Bronconeumol* 1998; 34 (Supl 2): 3-10.
15. Molinos L, Fernández R, Gullón JA, Rubinos G, Alonso MA, Escudero C, et al. Neumonía adquirida en la comunidad con tratamiento hospitalario. Interés de la clínica y exámenes complementarios en la predicción de la etiología. *Arch Bronconeumol* 1997; 33: 230-5.
16. Fang GD, Fine M, Orloff J., Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. *Medicine (Baltimore)* 1990; 69:307-16.
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Wissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997; 336: 243-50.
18. Fine MJ, Hough LJ, Medgser AR, Li AR, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcome Research Team Cohort Study. *Arch Intern Med* 1997; 157: 36-44.
19. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcome in community-acquired pneumonia. *Semin Respir Infect* 1993; 8:140-52.
20. Farr BM. Prognosis and decisions in pneumonia. *N Engl J Med* 1997; 336: 288-9.

21. Wennberg JE, Freeman JL, Culp WJ. Are hospital services rationed in New Haven or over-utilised in Boston? *Lancet* 1987; 1: 1185-89.
22. Torres A, El-Ebiary, M. Prognosis factors in severe community-acquired pneumonia: A step forward. *Intensive Care Med* 1996; 22: 1288-90.
23. Olaechea PM, Quintana JM, Gallardo MS, Insausti J, Maraví E, Álvarez B. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. *Intensive Care Med* 1996; 22: 1294-300.
24. Alfageme Michavila I, Muñoz Méndez J, de la Cruz Morón I. Neumonía comunitaria. Epidemiología. Factores de riesgo y pronóstico. *Arch Bronconeumol* 1998; 34 (supl 2):17-24.
25. Gonda MA, Braun MJ, Clement JE, Pyper JM, Wong-Staal F, Gallo RC, et al. Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses. *Proc Natl Acad Sci USA* 1986; 83: 4007-11
26. Levy J. Pathogenesis of Human Immunodeficiency Virus Infection. *Microbiol Rev* 1993; 57: 183-289.
27. Weiss R A. How does HIV cause AIDS? *Science* 1993; 260: 1273-9.
28. Pantaleo G, Fauci A. New concepts in the immunopathogenesis of HIV infection. *Ann Rev Immunol* 1995; 13: 487-512.
29. Fauci A. Host factors and the pathogenesis of HIV-induced disease. *Nature* 1996; 384:529-34.
30. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science* 1998; 280: 1884-8.
31. Stanley S, Ostrowski M, Justement J, Gault K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with HIV-1. *N Engl J Med* 1996; 334: 1222-30.
32. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infections is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature* 1993; 362: 355-8.

33. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, *et al.* Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 1997; 278: 1295-300.
34. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, *et al.* Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* 1997; 278: 1291-5.
35. Virelizier J. Cellular activation and HIV infection. *Curr Opin Immunol* 1990; 2: 409-13.
36. van Haastrecht HJ, van den Hoek AJ, Coutinho RA. High mortality among HIV-infected injecting drug users without AIDS diagnosis: implications for HIV infection epidemic modellers? *AIDS* 1994; 8: 363-6.
37. Muga R, Egea JM, Navio M, Sirera G, Vall M, Tor J. Mortalidad en una cohorte de drogadictos intravenosos del Área de Barcelona. *Med Clin (Barc)* 1999;112:721-5.
38. Levine DP, Brown PD. Infections in injection drug users. En : Mandell GL, Bennett JE, Dolin R, Editores. Principles and practice of Infections Disease. Fifth edition. Philadelphia:Churchill Livingstone, 2000, p. 3112-26.
39. Vergara de Campos A, Cruz Rosales E, Jurado Jiménez R. Infecciones del paciente usuario de drogas parenterales. En: La infección por el VIH: Guía práctica. Junta de Andalucía. Consejería de Salud. Sociedad Andaluza de Enfermedades Infecciosas, 2000.
40. Mientjes GH, Spijkerman JB, Amaejden EJC, van den Hock, JAR, Coutinho RA. Incidence and risk factors for pneumonia in HIV-infected and non-infected drug users. *J Infect Dis* 1996; 32: 181-6.
41. Boschini A, Smacchia C, Di Fine M, Schiesari A, Ballarini P, Arlotti M, *et al.* Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: Incidence, etiologies, and clinical aspects. *Clin Infect Dis* 1996, 23: 107-13.
42. Klimas NG, Blaney NT, Morgan RO, Chitwood D, Milles K, Lee H, *et al.* Immune function and anti-HTLV-I/II status in anti-HIV-1 negative intravenous drug users receiving methadone. *Am J Med* 1991; 90: 163-70.

43. Castilla J. Epidemia en España y en el mundo. En: Soriano V, González-Lahoz J, Editores. Manual del SIDA. 4ª ed. Barcelona: Publicaciones Permanyer S.L.; 2001.
44. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Dozin AM, Friedland GH, *et al.* Inability to predict diagnosis in febrile intravenous drug users. *Ann Intern Med* 1987; 106: 823-8.
45. Schoenbaum E, Hartel D, Selwyn PA., Klein RS, Davenny K, Rogers M, *et al.* Risk factors for human immunodeficiency virus infection in intravenous drug user. *N Engl J Med* 1989; 321: 874-79.
46. Schoenbaum E, Hartel D, Friedland G. HIV infection and intravenous drug use. *Curr Opin Infect Dis* 1990; 3: 80-93.
47. Vlahov D, Muñoz A, Anthony JC, Cohn S, Celentano DC, Nelson D. Association of drug injection patterns with antibody to human immunodeficiency virus type I among intravenous drug users in Baltimore, Maryland. *Am J Epidemiol* 1990; 132: 847-56.
48. Saracco A, Musicco M, Nicolosi A, Angarano G, Arici C, Gavazzeni G, *et al.* Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. *J Acquir Immune Defic Syndr* 1993; 6: 497-502.
49. Solomon L, Astemborsky J, Warrem D, Muñoz A, Conh S, Vlahov D, *et al.* Differences in risk factors for human immunodeficiency virus type I seroconversion among male and female intravenous drug users. *Am J Epidemiol* 1993; 137: 892-8.
50. Astemborski J, Vlahov D, Warren D, Solomon L, Nelson KE. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. *Am J Public Health* 1994; 84: 382-7.
51. Egea JM, Tor J, Muga R, Roca J, Rodríguez R, Navio M, *et al.* Tasas de infección por el VIH en drogadictos intravenosos del área de Barcelona, según sexo y edad de inicio en el consumo. *Med Clin (Barc)* 1996; 106: 87-90.
52. Fernández M, Gómez M, Delgado M, Gálvez R. Infección por el virus de la inmunodeficiencia humana en la población española (II). Metaanálisis de las tendencias temporales y geográficas. *Med Clin (Barc)* 1990; 95: 366-71.

53. Zulaica D, Pérez-Trallero E, Arrizabalaga J. Prevalencia de infección a retrovirus HTLV-III en heroinómanos. *Med Clin (Barc)* 1985; 85: 727-9.
54. Miró JM, Trilla A. Infecciones en drogadictos en España: impresiones 10 años después. *Enferm Infecc Microbiol Clin* 1990; 9: 473-7.
55. Muga R, Egea J, Tor J, Rodríguez R, Roca J, Giménez G, *et al.* Desciende la infección por el VIH en drogadictos intravenosos de Barcelona: 1987-1993. *Med Clin (Barc)*. 1994; 567-70.
56. Sopelana P, Carrascosa C, García-Benito P. Evolución de la prevalencia de la Infección por el VIH-1 en los drogodependientes de la Comunidad de Madrid (1985-1996). *Med Clin (Barc)* 1998; 111: 257-8.
57. Hernández Aguado I, Aviñó M, Pérez-Hoyos S, González-Aracil J, Ruiz-Pérez I, Torrella A, *et al.* Human immunodeficiency virus (HIV) infection in parenteral drug users: evolution of epidemic over 10 years. Valencian Epidemiology and Prevention of HIV Disease Study Group. *Int J Epidemiol* 1999, 28: 335-40.
58. Castilla J, de la Fuente L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980-1998. *Med Clin (Barc)* 2000; 115: 85-9.
59. Cañas García-Otero E, Viciano Fernández P, Lozano de León-Naranjo F, Torres Tortosa M (Coord.). La infección por el VIH en Andalucía. Una década de encuestas hospitalarias de prevalencia. Sociedad Andaluza de Enfermedades Infecciosas. Sevilla: Impresiones del Sur, S.L.;2001.
60. Caylà JA, Marco A, Bedoya A, Guerrero R, Garcia J, Martín V, Jansa JM, De Olalla PG, Selwyn PA. Differential characteristics of AIDS patients with a history of imprisonment. *Int J Epidemiol* 1995; 24: 1188-96.
61. Muñoz A, Schragger LK, Bacellar H, Speizer I, Vermund SH, Detels R, *et al.* Trends in the incidence of outcome defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. *Am J Epidemiol* 1993; 137: 423-38.
62. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, *et al.* Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998; 338: 853-60.

63. Alberdi J, López-Gay D, Ferreiras A, Nieto E. Descenso brusco de la mortalidad por VIH/sida en la Comunidad de Madrid. *Med Clin (Barc)* 1998; 110: 679.
64. García de Olalla P, Caylà JA, Brugal MI, Galdós H, Jansá JM, Clos R. Evolución de la mortalidad y supervivencia del SIDA en Barcelona (1981-1997). *Med Clin (Barc)* 1999; 113: 169-70.
65. De la Fuente L, Barrio G, Vicente J, Bravo MJ, Santacreu J and the Spanish Group for the Study of the Purity of Seized Drugs. Temporal and geographic variations in the characteristics of the heroin seized in Spain and their relation with the route of administration. *Drug Alcohol Depend* 1996; 40:185-94.
66. Cañas García-Otero EJ, García León FJ. Epidemiología de la infección por el VIH y SIDA. En: La infección por el VIH. Guía práctica. Junta de Andalucía. Consejería de Salud. Sociedad Andaluza de Enfermedades Infecciosas, 2000.
67. Des Jarlais DC, Friedman SR, Sotheran JL, Wenston J, Marmor M, Yancovitz SR, *et al.* Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. *JAMA* 1994; 271: 121-7.
68. Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G, Cartenter C, Skowron G, Mayer, K. Causes of death in persons with human immunodeficiency virus infection. *Am J Med* 1992; 93: 387-90.
69. Chan ISF, Neaton JD, Saravolatz LD, Crane LR, Osterberger J. Frequencies of opportunistic diseases prior to death among HIV-infected persons. *AIDS*. 1995; 9: 1145-51.
70. Wolff M, Bedos JP, Bruneel F, Thuong M, Régnier B, Vachon F. Les complications pulmonaires graves au cours de l'infection par le VIH. *Réan Urg* 1998; 7: 557-69.
71. Paul S, Gilbert HM, Zieheck W, Jacobs J, Sepkowitz KE. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. *AIDS* 1999;13:415-8.

72. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. *Ann Intern Med* 1995; 123: 933-940.
73. Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, Stover DE, *et al.* Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute Workshop. *N Engl J Med* 1984; 310: 1682-88.
74. Murray JF, Garay MS, Hopewell PC, Mills S, Snider GL, Stover DE. Pulmonary complications of the acquired immunodeficiency syndrome. An update. Report of the Second National Heart, Lung, and Blood Institute Workshop. *Am Rev Respir Dis* 1987; 135: 504-9.
75. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RE, *et al.* Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. *N Engl J Med* 1992; 327: 1697-703.
76. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, *et al.* Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. *New Engl J Med* 1995, 333: 845-51.
77. Polsky B, Gold JW, Whimbey E, Dryjanski J, Brown AE, Schiffman G, *et al.* Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104: 38-41.
78. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. *Am J Med* 1987; 82: 900-6.
79. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, *et al.* Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. *AIDS* 1988; 2: 267-72.
80. Gilks CF, Ojoo SA, Brindle RJ: Non-opportunistic bacterial infections in HIV-seropositive adults in Nairobi, Kenya. *AIDS* 1991; 5 (Suppl 1): 113-6.
81. Farizo KM, Buehler JM, Chamberland ME, Whyte BM, Froelicher ES, Hopkins SG, *et al.* Spectrum of disease in persons with human

- immunodeficiency virus infection in the United States. *JAMA* 1992; 267: 1798-805.
- 82.** Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 1992; 41(RR-17): 1-19.
- 83.** Soriano V, Valencia E, Alba A, Laguna F, Moreno V, Alberdi JC, García-Samaniego J, González-Lahoz J. Cambios en el espectro de enfermedades en pacientes hospitalizados con infección por el VIH. *Med Clin (Barc)* 1993; 101: 736-40.
- 84.** Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. *Lancet* 1998; 351: 228-30.
- 85.** Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, *et al.* HIV infection induces changes in CD4 + T-cell phenotype and depletions within the CD4 T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. *Nat Med* 1997; 3: 533-40.
- 86.** De Gaetano Donati K, Bertagnolio S, Tumbarello M, Tacconlli E, Cataldo M, Longo B, *et al.* Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV infected subjects. *Int J Antimicrob Agents* 2000; 16: 357-60.
- 87.** Valencia ME, Martín-Carbonero L, López M, Soriano V, Moreno V, González Lahoz J. Motivo de ingreso hospitalario en pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. *Med Clin (Barc)* 2002; 119: 293-5.
- 88.** Martínez E, Marcos A, Mensa J. Neumonía adquirida y tratada en la comunidad en el paciente VIH positivo. *Enfer Infecc Microbiol Clin* 1999; 17 (Supl 1): 47-52.
- 89.** Cohn DL. Bacterial pneumonia in the HIV-infected patient. *Infect Dis Clin North Am* 1991; 5: 485-507.
- 90.** Nichols L, Balogh K, Silverman M. Bacterial infections in the acquired immunodeficiency syndrome: clinicopathologic correlations in a series of autopsy cases. *Am J Clin Pathol* 1990; 92: 787-90

91. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy finding. *Chest* 1998; 113: 1225-9.
92. Farley MM, Stephens DS, Brachman PS, Brachman PS, Harvey RC, Smith JD, *et al.* Invasive *Haemophilus influenzae* disease in adults: a prospective, population-based surveillance. CDC Meningitis Surveillance Group. *Ann Intern Med* 1992; 116: 806-12.
93. Schuchat A, Broome CV, Hightower A, Costa SJ, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. *JAMA* 1991; 265: 3275-79.
94. Muñoz A, Vlahov D, Solomon L, Margolick JB, Bareta JC, Cohn S, *et al.* Prognostic indicators for development of AIDS among intravenous drug users. *J Acquir Immune Defic Syndr* 1992; 5: 694-700.
95. Mientjes GH, van Ameijden EJC, Weigel HM, van den Hoed JAR, Coutinho RA. Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected misusers of intravenous drugs. *Br Med J* 1993; 6: 371-3.
96. Margolick JB, Muñoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, *et al.* Changes in T-lymphocyte subsets in intravenous drug users with HIV-infection. *JAMA* 1992; 267: 1631-6.
97. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, *et al.* Community-acquired pneumonia: impact of immune status. *Am J Resp Crit Care Med* 1995; 152: 1305-15.
98. Tumbarello M, Tacconelli E, Gaetano K, Cauda R. HIV-Associated bacterial pneumonia in the era of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr Hum Retrovirol* 1999; 20: 208-9.
99. Clavo-Sánchez AJ, Girón-González JA, López-Prieto D, Torres-Tortosa M, Sánchez-Porto A. Influence of CD4+ status on the invasiveness of pneumococcal pneumonia in HIV patients. *Eur J Clin Microbiol Dis* 1996; 15: 959-60.

100. Des Jarlais DC, Friedman SR, Choopany K, Vanichseni S, Ward TP. International epidemiology of HIV and AIDS among injecting drug users. *AIDS* 1992; 6: 1053-68.
101. García-Leoni ME, Moreno S, Rodeño P, Cercenado E, Vicente T, Bouza E. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. *Arch Intern Med* 1992, 152: 1808-12.
102. Greenberg AE, Thomas PA, Landesman SH, Mildvan D, Seidlin M, Friedland GH, *et al.* The spectrum of HIV-1 related disease among outpatients in New York City. *AIDS* 1992; 60: 849-59.
103. Mientjes GH, van Ameijden EJ, van den Hoek AJ, Coutinho RA. Increasing morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam. *AIDS* 1992; 6: 207-12
104. Caiaffa WT, Graham NM, Vlahov D. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. *Am J Epidemiol* 1993; 138: 909-22.
105. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, *et al.* Respiratory disease trends in the Pulmonary Complications of HIV Infection Study Cohort. Pulmonary Complications of HIV Infection Study Group. *Am J Respir Crit Care Med* 1997;155: 72-80.
106. Breiman RF, Spika JS, Navarro VJ, Darden PM, Darby CP. Pneumococcal bacteremia in Charleston County, South Carolina: a decade later. *Arch Intern Med* 1990; 150: 1401-5.
107. Heffner JE, Harley RA, Schabel SI. Pulmonary reactions from illicit substance abuse. *Clin Chest Med* 1990;11:151-62.
108. Mientjes GH, Miedema F, van Ameijden EJ, van den Hoek AA, Schellekens PT, Roos MT, *et al.* Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. *AIDS* 1991;5:35-41.
109. Caiaffa WT, Vlahov D, Graham NMH, Astemborski J, Solomon L, Nelson DE, *et al.* Drug smoking, *Pneumocystis carinii* pneumonia and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. *Am J Respir Crit Care Med* 1994;150:1493-8.

110. Mégarbane B, Bruneel F, Chevret S, Thuong M, Wolff M, Régnier B, *et al.* Les pneumonies bactériennes communautaires graves à *Streptococcus pneumoniae* chez les patients infectés par le VIH: épidémiologia et facteurs pronostiques de décès. *Path Biol* 1999; 47: 422-9.
111. Almirall J, Bolibar I, Balanzo X, González, CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. *Eur Respir J* 1999; 13: 349-55.
112. Farr BM, Bartlet CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. *Respir Med* 2000; 94: 954-63.
113. Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The association between cigarette smoking and selected HIV-related medical conditions. *AIDS* 1996; 10: 1121-6.
114. Burns DN, Hillman D, Neaton JD, Sherer R, Mitchell T, Capps L, *et al.* Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection: Terry Bein Community Programs for Clinical Research on AIDS. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996; 13: 374-383.
115. Flanigan TP, Hogan JW, Smith D, Schoenbaum E, Vlahov D, Schuman P, Mayer K. Self-reported bacterial infections among women with or at risk for human immunodeficiency virus infection. *Clin Infect Dis* 1999; 29: 608-12.
116. Mayer H, Rose D, Cohen S. The effect of *Pneumocystis carinii* pneumonia prophylaxis regimens on the incidence of bacterial infections in HIV infected patients. *AIDS* 1993; 7: 1687-9.
117. Melnick SL, Sherer R, Louis TA, Hillman D, Rodríguez EM, Lackman C, *et al.* Survival and disease progression according to gender of patients with HIV infection. The Terry Bein Community Programs for Clinical Research on AIDS. *JAMA* 1994; 272:1915-21.
118. Backer V, Nybo Jensen B, Pedersen C, Hertz JB, Jensen TH. Time-related decrease in diffusion capacity in HIV-infected patients with impaired immune function. *Scand J Infect Dis* 1992; 42: 29-34.

119. Díaz PT, Clanton TL, Pacht ER, Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. *Ann Intern Med* 1992; 116: 124-8.
120. Beck JM, Shellito J. Effects of human immunodeficiency virus on pulmonary host defenses. *Semin Respir Infect* 1989; 4: 75-84.
121. Blaser MJ, Cohd DL. Opportunistic infections in patients with AIDS: Clues to the epidemiology of AIDS and the relative virulence of pathogens. *Rev Infect Dis* 1986; 8: 21-30.
122. Toews GB. Predisposition to respiratory disease: immunologic and nonimmunologic factors. *Ann Intern Med* 1992; 117: 415-8
123. Balter M. How does HIV overcome the body's T cell bodyguards? *Science* 1997; 278:1399-400.
124. Ho DD, Neumann AU, Perelson AS, Chen WVA, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* 1995; 373: 123-6.
125. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1983;39:453-8.
126. Pahwa SG, Quiltop MT, Lange M, Pahwa RN, Grieco MH. Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. *Ann Intern Med* 1984;101:757-63.
127. Amman AJ, Shiffman G, Abramas D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. *JAMA* 1984; 251:1447-9.
128. Katz IRR, Krown SE, Safai B, Oettgen HF, Hoffmann MK. Antigen-specific and polyclonal B-cell responses in patients with acquired immunodeficiency disease syndrome. *Clin Immunol Immunopathol* 1986;39:359-67.
129. Dicipingaitis PV, Levy DE, Gnass RD, Bernstein RG: Pneumonia due to *Staphylococcus aureus* in patients with AIDS: Review of incidence and report of an atypical roentgenographic presentation. *South Med J* 1995; 88: 586-90.

130. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. *AIDS* 1989;3:37-9.
131. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical and immunologic perspectives. *Ann Intern Med* 1992; 117: 314-24.
132. Valone FH, Payan DG, Abrams DI, Goetzl EJ. Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. *J Infect Dis* 1984;150:267-71.
133. Ellis M, Gupta S, Galant S, Hakim S, Vande Ven C, Toy C, *et al.* Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. *J Infect Dis* 1988; 158: 1268-76.
134. Murphy PM, Lane HC, Fauci AS, Gallin JI: Impairment of neutrophil bactericidal activity in patients with AIDS. *J Infect Dis.* 1988; 158: 627-30.
135. Noskin GA, Glassroth J. Bacterial pneumonia associated with HIV-1 infection. *Clin Chest Med* 1996; 17: 713-23.
136. Nielsen H, Kharazmi A, Faber V. Blood monocyte and neutrophil functions in the acquired immune deficiency syndrome. *Scand J Immunol* 1986; 24: 291-296.
137. Moreno García M. Neutropenia en la infección por el VIH. *An Med Intern* 1997; 14:199-208.
138. Falcó V, Fernández de Sevilla T, Alegre J, Barbé J, Ferrer A, Ocaña I, *et al.* Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes. *Eur Respir J* 1994; 7: 235-39.
139. Burack JH, Hahn JA, Saint-Maurice D, Jacobson MA. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus tipe I infection: implications for rational empiric antibiotic therapy. *Arch Intern Med* 1994; 154: 2589-96.
140. Cordero E, Pachón J, Rivero A, Girón JA, Gómez-Mateos J, Merino MD, *et al.* The Grupo andaluz para el estudio de las enfermedades infecciosas. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. *Am J Respir Crit Care Med* 2000; 162: 2063-8.

141. Lesprit P, Decazes JM. Infections á pneumocoque chez le patient infecté par le VIH. *Presse Méd* 1997; 26: 243-7.
142. Cunha BA. Clinical approach to the HIV patient with community-acquired pneumonia. *Infect Med* 1999; 16: 798-800.
143. Amorosa JD, Nahass, RG, Noshier JL, Gocke D. Radiologic distinction of pyogenic pulmonary infection from *Pneumocystis carinii* pneumonia in AIDS patients. *Radiology* 1990; 175: 721-4.
144. Selwyn PA, Pumerantz AS, Durante A. Clinical predictors of *Pneumocystis carinii* pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. *AIDS* 1998;12:885-93.
145. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS defining illnesses in the era of antiretroviral combination therapy. *AIDS* 1997; 11:1731-8.
146. Janoff EN, O'Brien Thompson P, Ehret J, Meiklejohn G, Duvall G, *et al.* *Streptococcus pneumoniae* colonization, bacteremia and immune response among person with human immunodeficiency virus infection. *J Infect Dis* 1993; 167: 49-56.
147. Teira R, Virosta M, Muñoz J, Zubero Z, Cisterna R, Santamaría JM. Un estudio de cohortes históricas sobre las neumonías bacterianas como predictores de progresión de la enfermedad por virus de la inmunodeficiencia humana. *Enferm Infecc Microbiol Clin* 1997; 15: 418-21.
148. Jones JL, Hanson DL, Dworkin MS, Kaplan JE, Ward JW. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. *J Infect Dis* 1998; 178: 114-20.
149. Perucci CA, Davoli M, Rapiti E, Abeni D, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. *Am J Public Health* 1991; 81: 1307-10.
150. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, *et al.* Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. *AIDS* 1994; 8: 345-50.
151. Halm EA, Teirstein AS. Management of community-acquired pneumonia. *N Engl J Med.* 2002; 347: 2039-2045.

-
152. Tumbarello M, Tacconelli E, de Gaetano K, Ardito F, Pirroni T, Cauda R, Ortona L. Bacterial pneumonia in HIV-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998; 18: 39-45.
 153. Miller RF, Foley, NM, Kessel D, Jeffrey AA. Community acquired lobar pneumonia in patients with HIV infection and AIDS. *Thorax* 1994; 49: 367-8.
 154. Masliah E, De Teresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. *AIDS* 2000; 14: 69-74
 155. Baril L, Astagneau P, Nguyen J, Similowski T, Mengual X, Beigelman C, *et al.* Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological and epidemiological study. *Clin Infect Dis* 1998; 26:964-71.
 156. Park DR, Sherbin VL, Goodman MS, Pacifico AD, Rubenfeld GD, Polissar NL, Root RK. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. *J Infect Dis* 2001; 184: 268-77.
 157. Cordero Matia M E. Neumonías bacterianas graves de adquisición comunitaria en pacientes con infección por el virus de la inmunodeficiencia humana. Factores asociados a la mortalidad y desarrollo de un sistema pronóstico [Tesis doctoral]. Universidad de Sevilla; 1999.
 158. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An Examination of its reliability and validity in a research setting. *Cancer* 1984; 53: 2002-7.
 159. Stein MD, Piette J, Mor V, Wachtel TJ, Fleishman J, Mayer KH, Carpenter CCJ. Differences in access to zidovudine among symptomatic HIV-infected persons. *J Gen Intern Med* 1991; 6: 35-40.
 160. Bone RC, Balk RA, Cerra FB. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and multiple-organ failure and guidelines for use of innovative therapies in sepsis. *Chest* 1992; 101: 1644-55.

161. Betriu C, Palau L, Gómez M, Sánchez A, Romero J, Picazo JJ. Bacteriemias en un hospital universitario: estudio de los agentes etiológicos y de sus patrones de sensibilidad. *Rev Clín Esp* 1999; 199: 503-10.
162. Torres A, El-Ebiary M, Marrades R, Miró JA, Gatell JM, Sánchez-Nieto J.M, *et al.* Aetiology and prognostic factors of patients with AIDS presenting life-threatening acute respiratory failure. *Eur Respir J* 1995; 8: 1922-8.
163. James L, Hoppe-Bauer JE. Processing and interpretation of lower respiratory tract specimens. En: Isenberg HD editor. *Clinical Microbiology Procedures Handbook*. Washington (DC): ASM; 1992.
164. Baselki US, Wunderink RG. Bronchoscopic diagnosis of pneumonia. *Clin Microbiol Rev* 1994;7:533-8.
165. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. *Mayo Clin Proc* 1975; 50: 339-44.
166. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 4th ed, approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997. Doc M7-A4 (ISBN 1-56238-309-4).
167. Piédrola de Angulo G, García Sanchez JE, Gómez-Lus Centelles ML, Torreblanca Gil. Recogida, transporte y conservación de las muestras. *Procedimientos en microbiología clínica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica*, 1993.
168. Castella J, Ancochea J, Llorente L, Puzo C, Sanchis J, Sueiro A, Xaubet A. Lavado broncoalveolar. Normativas SEPAR. *Arch Bronconeumol* 1997; 33:515-26.
169. Bartlett, J.G. Pneumonia in the patient with HIV infection. *Infect Dis Clin Noth Am* 1998; 12: 807-20.
170. Alves C, Nicolás JM, Miró JM, Torres A, Agustí C, González J, *et al.* Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. *Eur Respir J* 2001; 17: 87-93.
171. Almirall J, Casado M, Valls F, Morató I, Agudo A, Priu R, *et al.* Estudio prospectivo de las neumonías extrahospitalarias atendidas en un hospital general. Error diagnóstico. *Med Clin (Barc)* 1991;97:250-4.

172. Caylà JA, Jansà JM, Iglésias B, Artazcoz L, Plasencia A. Epidemiología del síndrome de inmunodeficiencia adquirida en Barcelona (1981-1991) (I). Estudio descriptivo y de tendencias temporales. *Med Clin (Barc)* 1993; 101: 286-93.
173. Stanton DL, Wu AW, Moore RD, Rucker SC, Piazza MP, Abrams JE, Chaisson RE. Functional status of persons with HIV infection in an ambulatory setting. *J Acquir Immune Defic Syndr* 1994; 7: 1050-56.
174. Keller DW, Breiman RF. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. *Clin Infect Dis* 1995; 21 (Suppl 1): 77-83.
175. Westerberg VS. Alcohol measuring scales may influence conclusions about the role of alcohol in human immunodeficiency virus (HIV) risk and progression to the acquired immunodeficiency syndrome (AIDS). *Am J Epidemiol* 1992;135:719-25.
176. Fernández-Solá J, Junqué A, Estruch R, Monforte R, Torres A, Urbano-Márquez A. High alcohol intake as a risk and prognostic factor of community-acquired pneumonia. *Arch Intern Med* 1995;155:1649-54.
177. Saitz R, Ghali WA, Moskowitz MA. The impact of alcohol-related diagnoses on pneumonia outcomes. *Arch Intern Med* 1997; 157: 1446-52.
178. O'Donnell AE, Pappas LS. Pulmonary complications of intravenous drug abuse. *Chest* 1988;94:251-4.
179. Des Jarlais DC, Friedman SR, Marmor M, Cohen H, Midvan D, Yancovitz S, et al. Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. *AIDS* 1987; 1: 105-111.
180. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection. The Pulmonary complications, ICU support, and Prognostic factors of hospitalized patients with HIV (PIP) study. *Chest* 2000; 117: 1017-22.
181. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of VIH infection before diagnosis of AIDS. *Br Med J* 1993; 307:20-23.

182. Teira R, Zubero Z, Muñóz J, Alvarez M, Cisterna R, Santamaría JM. Neumonía por bacterias no oportunistas en pacientes infectados por VIH. Incidencia y valoración de una aproximación no invasiva. *Enf Infecc Microbiol Clin* 1992;10:11-6.
183. Carpi J. Treating iv drug users- a difficult task. *AIDS Patient Care* 1987;1:21-4.
184. Biedma D, Bascuñana A, Viciano P, Causse M, Torres Tortosa M, Lozano de León F, *et al.* Experiencia clínica con zidovudina en pacientes con síndrome de inmunodeficiencia adquirida. Análisis de 117 casos. *Rev Clin Esp* 1992;191:187-92.
185. Dorrucchi M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G and the HIV Seroconversion Study. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. *AIDS* 1997;11:461-7.
186. Metha S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. *AIDS* 1997;11:1665-70.
187. Chaisson RE, Jeanne MD, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. *N Engl J Med* 1995; 333: 751-6.
188. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. *MMWR Recomm Rep* 1997;46 (RR-12):1-46.
189. McKenzie R, Travis, WD, Dolan SA, Pittaluga S, Feuerstein IM, Yarchoan R, *et al.* The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. *Medicine (Baltimore)* 1991; 70: 326-43.
190. López-Dupla M, Mora Sanz P, Pintado García V, Valencia Ortega E, Uriol PL, Khamashta MA, *et al.* Clinical, endoscopic, immunologic and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. *Am J Gastroenterol* 1992; 87: 1771-6.
191. Chaisson RE. Bacterial pneumonia in patients with human immunodeficiency virus infection. *Semin Respir Infect* 1989; 4: 133-8.

192. Kotler DP, Wang J, Pierson R, Holt PR. Body composition studies in patients with AIDS. *Am J Clin Nutr* 1985; 42: 1255-65.
193. Polo R. Nutrición en el paciente VIH. Reuniones de consenso sobre la infección por VIH. Atención integral al paciente con VIH. 1996; 60-69.
194. Soriano V, García-Samaniego J, Bravo R, Valencia E, Laguna F, de Poupiana M, *et al.* Morbilidad y mortalidad asociadas a hepatopatía crónica viral en pacientes infectados por el virus de la inmunodeficiencia humana. *Med Clin (Barc)* 1995; 104: 641-44.
195. Romeo R, Rumi MG, Donato MF, Gargnel MA, Vigano P, Mondelli M, *et al.* Hepatitis C is more severe in drug users with human immunodeficiency virus infection. *J Viral Hepat* 2000; 7: 297-301.
196. Huang L, Stansell JD. AIDS and the lung. *Med Clin N Am* 1996;80:775-801.
197. Amin Z, Miller RF, Shaw J. Lobar or segmental consolidation on chest radiographs of patients with HIV infection. *Clin Radiol* 1997; 52:541-5.
198. Montón C, Rañó A, Torres A. Respuesta inflamatoria en las neumonías. *Arch Bronconeumol* 1998; 34 (supl 2): 11-16.
199. Magnenat JL, Nicod LP, Auckenthaler R, Junod AF. Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients. *Am Rev Respir Dis* 1991; 144: 917-22.
200. Fernández Fabrellas E, González Constan E, Marín González M, León P, Blanquer Olivas R. Estudio de la inmunidad celular pulmonar en pacientes VIH. *An Med Interna* 1999; 16: 21-4.
201. Moreno S, Martínez R, Barros C, González-Lahoz J, García-Delgado E., Bouza E. Latent *Haemophilus influenzae* pneumonia in patients infected with HIV. *AIDS* 1991; 5: 967-70.
202. Cordero E, Pachón J, Rivero A, Girón JA, Gómez-Mateos J, Merino MD, *et al.* *Haemophilus influenzae* pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. *Clin Infect Dis* 2000; 30: 461-65.

203. Omar Mohamed M, Martín Rubio A, GómeZ-Vidal MA, Aliaga Martínez L, Hernández-Burruezo JJ. Neumonía por *Haemophilus influenzae* en pacientes con infección por el virus de la inmunodeficiencia humana. *Investig Clin* 2001; 4: 206-11.
204. Afessa B. Pleural effusion and pneumothorax in hospitalized patients with HIV. The Pulmonary complications, ICU support , and Prognostic factors of hospitalized patients with HIV (PIP) study. *Chest* 2000; 117: 1031-7.
205. Gallant JE, Ko AH. Cavitory pulmonary lesions in patients infected with human immunodeficiency virus. *Clin Infect Dis* 1996; 22:671-82.
206. Golpe Gómez R, Cifrián Martínez JM, Fernández Rozas SM, García Pérez MM, Mons Lera R, Jiménez Gómez A. Neumotórax espontáneo asociado a la infección por el virus de la inmunodeficiencia humana (VIH). *Arch Bronconeumol* 1998; 34: 184-8.
207. Sepkowitz KA, Telzak EE, Gold JW, Bernard EM, Blum S, Carrow M, et al. Pneumothorax in AIDS. *Ann Intern Med* 1991;114:455-9.
208. Wallace JM, Rao AV, Glassroth J, Hansen NI, Rosen MJ, Arakaki C, et al. Respiratory illness in persons with human immunodeficiency virus infection. *Am Rev Resp Dis* 1993;148: 1523-9.
209. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of *Pneumocystis* prophylaxis. Multicenter AIDS Cohort Study. *N Engl J Med* 1993;329:1922-6.
210. Redd SC, Rutherford GW, Sande MA, Lifson AR, Hadley WK, Facklam RR, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. *J Infect Dis* 1990; 162: 1012-7.
211. Lieberman D. Atypical pathogens in community-acquired pneumonia. *Clin Chest Med* 1999; 20: 489-97.
212. Allan AA, Kamholz SL. *Legionella pneumonia* and AIDS. *Chest* 1989; 95: 707-708.
213. Visco Comandini U, Maggi P, Santopadre P, Monno R, Angarano G, Vullo V. *Chlamydia pneumoniae* respiratory infections among patients infected with the Human Immunodeficiency Virus. *Eur J Microbiol Infect Dis* 1997; 16: 720-26.

214. Blasi F, Cosentini R, Clerici Schoeller M, Lupo A, Allegra L. *Chlamydia pneumoniae* seroprevalence in immunocompetent and immunocompromised populations in Milan. *Thorax* 1993; 48: 1261-3.
215. Blasi F, Boschini A, Cosentini R, Delfino Legnani D, Smacchia C, Ghira C, et al. Outbreak of *Chlamydia pneumoniae* infection in former injection-drug users. *Chest* 1994; 105: 812-5.
216. Visco Comandini U, Massetti AP, Marchese R, Zaccarelli M, Vullo V, Delia S. *Chlamydia pneumoniae* seroprevalence among HIV-infected and uninfected people with known HIV risk factors. *AIDS* 1996; 10: 1543-7.
217. Muñoz P, García-Paredes P, Bouza Santiago E. *Chlamydia* como agente responsable de enfermedad en el paciente inmunodeprimido y trasplantado. *Rev Clin Esp* 1998; 198 (Sup 1): 35-40.
218. De Gracia J, Miratvilles M, Mayordomo, Ferrer A, Álvarez A, Bravo C, Vendrell M. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. *Chest* 1997;111:1180-6.
219. Jensen BN, Gerstoft J, Skinhoj P. The prognosis in HIV-infected patients with pneumonia. Relation to microbiological diagnoses. *Dan Med Bull* 1991; 38: 468-70.
220. García Rey C, Bouza Santiago E. Neumonía bacteriana mixta. *Med Clin (Barc)* 1998; 110 (Supl 1): 36-9.
221. Aliaga L, Mediavilla JD, López Gómez M, Alados JC, González de Vega JM, de la Rosa M. Utilidad del lavado broncoalveolar en el diagnóstico de la infección respiratoria en pacientes HIV. *Rev Med Univ Navarra* 1997; 41: 217-23.
222. Broaddus C, Dake MD, Stulbarg MS, Blumenfeld W, Hadley WK, Golden JA, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985;102:747-52.
223. De Gracia J, Curull V, Riba A, Orriols R, Tallada N, Serra J, et al. Importancia del lavado broncoalveolar en el diagnóstico temprano de la afección pulmonar difusa en el paciente inmunodeprimido. *Med Clin (Barc)* 1987; 89:728-32.

-
224. Sauleda J, Maimó A, Riera M, Ramírez J, Togores B, Pons S, *et al.* A new bronchoscopic technique for the diagnosis of bacterial pneumonia in HIV-positive patients. *Respir Med* 1997; 91: 530-6.
225. Cordero E, Pachón J, Rivero A, Girón-González JA, Gómez-Mateos J, Merino MD, *et al.* Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. *Eur J Clin Microbiol Infect Dis* 2002, 21: 362-7.
226. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ. *Streptococcus pneumoniae* infections and bacteremia in patients with acquired immunodeficiency syndrome with report of a pneumococcal vaccine failure. *Am Rev Respir Dis* 1984; 130: 1174-6.
227. Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease. Clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. *Clin Infect Dis* 1996; 23: 577-84.
228. Cordero E, Bouza E, Ruíz I, Pachón J. Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. *J Antimicrob Chemother* 2001; 48: 527-34.
229. Baron AD, Hollander H. *Pseudomonas aeruginosa* bronchopulmonary infection in late human immunodeficiency virus disease. *Am Rev Respir Dis* 1993;148:992-6.
230. Schuster MG, Norris AH. Community-acquired *Pseudomonas aeruginosa* pneumonia in patients with HIV infection. *AIDS* 1994;8:1437-41.
231. Ali NJ, Kessel D, Miller RF. Bronchopulmonary infection with *Pseudomonas aeruginosa* in patients infected with human immunodeficiency virus. *Genitourin Med* 1995;71:73-7.
232. Arrizabalaga Aguirreazaldegui JP, Horcajada Gallego JP, Mentxaka Ugalde B, Rodríguez Arrondo F, Iribarren Loyarte JA, von Wichman de Miguel MA, *et al.* Infección respiratoria por *Pseudomonas aeruginosa* en pacientes con infección por el VIH. *Rev Clin Esp* 1996;196:678-83.

-
233. Elvira J, López-Suárez A, Clavo A, Piña JM, Segura E, Pérez-Guzmán E, *et al.* Infección por *Pseudomonas aeruginosa* en pacientes infectados por el virus de la inmunodeficiencia humana. Estudio descriptivo de 35 casos. *Enferm Infecc Microbiol Clin* 1998; 16:322-7.
234. Meynard JL, Barbut F, Guiguet M, Batisse D, Lalande V, Lesage D, *et al.* *Pseudomonas aeruginosa* infection in human immunodeficiency virus infected patients. *J Infet* 1999; 38:176-81.
235. De Palo V, Millstein MD, Mayo PH, Salzman SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. *Chest* 1995;107:506-10.
236. Rosen MJ, Clayton K, Schneider RF, Fulkerson W, Rao AV, Stansell J, *et al.* Intensive care of patients with HIV infection. Utilization, critical illnesses and outcomes. *Am J Respir Crit Care Med* 1997;155:67-71.
237. Álvarez Lérma F, Miguel Cisneros J, Fernández-Viladrich P, León C, Miró JM, Pachón J, *et al.* Indicaciones de ingreso en el servicio de medicina intensiva de pacientes adultos con infecciones graves. *Enferm Infecc Microbiol Clin* 1998; 16: 423-30.
238. Pachón J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. *Am Rev Respir Dis* 1990;142: 369-73.
239. Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis in outcome. *Chest* 1993;103;232-5.
240. Almirall J, Mesalles, Klamburg J, Parra O, Agudo A. Prognostic factors of neumonia requiring admission to the intensive care unit. *Chest* 1995;107:511-6.
241. Leroy O, Santré C, Beuscart C, Georges H, Guery B, Jacquier JM, *et al.* A five year study of severe community acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. *Intensive Care Med* 1995;21:24-31.
242. Wu AW, Mathews WC, Brysk LT, Atkinson JH, Grant I, Abramson I, *et al.* Quality of life in a placebo-controlled trial of Zidovudine in patients with AIDS and AIDS-related complex. *J Acquir Immune Defic Syndr* 1990; 3: 683-90.

-
243. Moore RD, Hidalgo J, Suglan BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. *N Engl J Med* 1991; 324: 1412-6.
244. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with HIV disease, as measured by the Medical Outcomes Study Instrument. *Ann Intern Med* 1992; 116: 129-37.
245. Badia X, Guerra L, García M, Podzamczar D. La evaluación de la calidad de vida en los pacientes con infección por el VIH y sida. *Med Clin (Barc)* 1999; 112: 739-44.
246. Thyrault M, Gachot B, Chastang C, Souweine B, Timsit JF, Bédos JP, Régnier B, Wolff M. Septic shock in patients with the acquired immunodeficiency syndrome. *Intensive Care Med* 1997; 23: 1018-23.
247. Torres JM, Cárdenas O, Vasquez A, Schlossberg D. *Streptococcus pneumoniae* bacteremia in a community hospital. *Chest* 1998; 113: 387-90.
248. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre la neumonía adquirida en la comunidad. *Arch Bronconeumol* 2001; 37: 340-8.
249. Tumbarello M, Tacconelli E, Lucia MB, Cauda R, Ortona L. Predictors of *Staphylococcus aureus* pneumonia associated with human immunodeficiency virus infection. *Respir Med* 1996; 90: 531-37.
250. Levine SJ, White DA, Fels AO. The incidence and significance of *Staphylococcus aureus* in respiratory cultures from patients infected with the human immunodeficiency virus. *Am Rev Respir Dis* 1990;141:89-93.
251. Kulhs TL, Viering TP, Leach CT, Steele MI, Haglund LA, Fine DP. Relapsing pneumococcal bacteremia in immunocompromised patients. *Clin Infect Dis* 1992;14:1050-4.
252. Masur H, Kaplan JE, King KH. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Health Service and the Infectious Diseases Society of America. *Ann Intern Med* 2002; 137: 435-77.

